Core Viewpoint - Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares for gross proceeds of up to $600 million, with the meeting scheduled for September 26, 2025 [1][2]. Group 1: Offering Details - The entire offering is expected to be subscribed by existing holders of MVS and is anticipated to close on or about September 26, 2025, pending shareholder approval [2]. - Proceeds from the offering will be used for general working capital purposes [2]. - All securities issued will be subject to a statutory hold period of four months plus a day from issuance in accordance with Canadian securities laws [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [5]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [5]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will drop to 3% [5].

Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that the Positron Emission Tomography (PET) tracer used in a joint study with Massachusetts General Hospital (MGH) scientists shows ...

Core Insights - Quantum BioPharma Ltd. has received a clinical study report (CSR) confirming the safety and tolerability of its compound Lucid-MS in a Phase 1 trial involving healthy participants [1][3][4] - Lucid-MS is a first-in-class neuroprotective compound aimed at treating multiple sclerosis (MS) and has demonstrated the ability to prevent demyelination in preclinical models [2][5] - The company is preparing to advance the clinical development of Lucid-MS towards efficacy trials in MS patients following the positive CSR results [4][5] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, in its portfolio [5] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [5] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial properties [5]

Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities in a market manipulation lawsuit, alleging damages exceeding $700 million USD due to "spoofing" techniques that artificially depressed its stock price [1][2][4]. Legal Proceedings - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants engaged in market manipulation that violated the Securities Exchange Act of 1934 [2]. - Quantum BioPharma's amended complaint was filed on May 31, 2025, in response to the defendants' memorandum of law filed on June 16, 2025 [2][3]. Financial Implications - Quantum BioPharma is seeking over $700 million USD in damages due to the alleged market manipulation [2]. - The company's stock was trading over $460 USD per share in January 2020, with a market capitalization approaching $1 billion USD [5]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted an extensive investigation and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Background - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement that could yield up to $250 million [10].

Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities, alleging market manipulation that harmed the company's stock price and seeking over $700 million in damages [1][2]. Legal Proceedings - The company filed an amended complaint on May 31, 2025, alleging that the defendants engaged in market manipulation schemes violating the Securities Exchange Act of 1934 [2]. - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants used "spoofing" techniques to manipulate Quantum BioPharma's share price [2][4]. - The company has made all relevant legal documents available on its website for public access [3]. Financial Impact - Quantum BioPharma's stock was trading over $460 per share in January 2020, with a market capitalization nearing $1 billion [5]. - The company is seeking damages exceeding $700 million due to the alleged manipulation, which it claims has significantly harmed both the company and its investors [2][4]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted extensive investigations and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [10]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., with a royalty agreement that could yield significant future revenue [10].

Core Viewpoint - Quantum BioPharma Ltd. announced that its subsidiary, Unbuzzd Wellness Inc., is launching a Regulation D 506(c) offering to raise up to US$5 million for growth and a potential initial public offering, which will not dilute Quantum BioPharma shareholders [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [6]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has an agreement for royalty payments of 7% of sales from Unbuzzd until total payments reach US$250 million, after which the royalty rate drops to 3% [6]. Product Information - Unbuzzd is a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, developed by a team with expertise in pharmacology and medicine [8][9]. - Clinical trials have shown that Unbuzzd can reduce blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, improve alertness, and lessen hangover symptoms significantly [10][13]. Capital Raising Strategy - Unbuzzd has partnered with MZ Digital and Dealmaker to conduct the capital raise campaign, allowing investments through traditional and cryptocurrency payments [3]. - The offering aims to support direct-to-consumer, distributor, and retail expansion plans for Unbuzzd [5].

Core Insights - Quantum BioPharma Ltd. has submitted its patented drug candidate Lucid-21-302 (Lucid-MS) for the Innovative Licensing and Access Pathway (ILAP) Passport program in the UK, aiming to provide a new treatment for multiple sclerosis (MS) [1][3] Group 1: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [4] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models [4] - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty will drop to 3% [4] Group 2: ILAP Passport Program - The ILAP Passport is designed to expedite the development and delivery of groundbreaking medicines by fostering collaboration among medicine developers, regulatory bodies, and the NHS [2] - The program aims to streamline the process of developing, reviewing, approving, and delivering new treatments to patients, ensuring timely access to medical innovations [2] Group 3: Statements from Company Executives - Dr. Andrzej Chruscinski expressed excitement about the ILAP Passport submission, highlighting its potential to accelerate clinical development and patient access to Lucid-21-302 [3] - Dr. Lakshmi P. Kotra emphasized the company's commitment to bringing innovative drugs to patients quickly and the importance of global regulatory strategies [4]

Core Viewpoint - Quantum BioPharma Ltd. is completing a non-brokered private placement of class A multiple voting shares at a price of $50 per share, aiming for gross proceeds of up to $600 million, expected to be fully subscribed by existing holders of MVS [1][3]. Group 1: Offering Details - The Offering consists of class A multiple voting shares priced at $50 each, with total gross proceeds anticipated to reach $600 million [1]. - All securities issued in the Offering are subject to a statutory hold period of four months plus a day from issuance, in accordance with Canadian securities laws [2]. - The proceeds from the Offering will be utilized for general working capital purposes [2]. Group 2: Insider Participation - The Offering is expected to be fully subscribed by Xorax Family Trust and Fortius Research and Trading Corp., both of which have insider connections to the Company [3]. - The participation of these insiders is classified as a "related-party transaction" under Multilateral Instrument 61-101, with exemptions from formal valuation and minority shareholder approval requirements being relied upon [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [6]. - The Company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% on sales until reaching $250 million, after which the royalty rate will decrease to 3% [6].

Core Insights - Quantum BioPharma Ltd. has engaged MZ Digital and Dealmaker to raise up to US$5 million through a Regulation D 506(c) offering for Unbuzzd Wellness Inc., which produces a beverage that accelerates alcohol metabolism and reduces hangover symptoms [1][2] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [3] - Unbuzzd Wellness Inc. is a public issuer that offers a scientifically backed beverage designed to help alcohol consumers manage their consumption and recovery [5] Product Details - Unbuzzd is a proprietary blend of vitamins, minerals, and herbs that aids in faster alcohol metabolism, restores mental clarity, and improves cognition [5] - Clinical trials have shown that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, with significant improvements in alertness and reduced hangover symptoms [6][7][14] Financial Aspects - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments on sales until reaching $250 million, after which the royalty rate drops to 3% [3]

Core Viewpoint - Quantum BioPharma Ltd. announces that Unbuzzd Wellness Inc. is raising up to US$5 million through a Regulation D 506(c) offering to support its expansion plans for the unbuzzd™ beverage, which accelerates alcohol metabolism and reduces hangover symptoms [1][2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [3] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments on unbuzzd™ sales until reaching $250 million, after which the royalty rate drops to 3% [3] Product Details - Unbuzzd™ is a scientifically-backed beverage designed to help alcohol consumers process alcohol faster, restore mental clarity, and alleviate hangover symptoms [5][6] - Clinical trials show that unbuzzd accelerates alcohol metabolism, reducing blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [6][13] - Participants reported significant improvements in alertness and reductions in hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [13] Leadership and Strategy - John Duffy, CEO of Unbuzzd, emphasizes the commitment to providing a scientifically backed product to alcohol consumers and the importance of the capital raise for expansion [2] - Gerry David, Board Co-Chair, highlights that the capital raise will support company growth and position unbuzzd for a potential initial public offering [3]